2015 outlook for US and EU pharma; report

According to this Global Pharma US & EU Outlook 2015 report, strategy diversification stays divested as productivity measurements, divestment of non-core assets result in healthy cash position and will accelerate next wave of targeted acquisition.

In the recent years, several new therapies have been approved in the area of diabetes (SGLT-2, GLP-1 agonists), multiple sclerosis (MS), hepatitis C virus (HCV), melanoma and breast cancer from major pharmaceutical companies. Many of them are expected to reach multibillion dollars peak sales in the near-term which is likely to compensate the patent expiry loss in top-line revenue, according to the report.

Novel mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors have also got exclusive attention by large cap Pharma companies. Most companies are in race to acquire assets in these hot therapy areas. Companies who already have these assets are investing heavily in clinical development programs. The interest in pursuing opportunities in Oncology therapy is unhindered for all major Pharma companies. Research investments in oncology likely to continue for several more years due to the significant unmet need exist in this area.